NCT00990756View on ClinicalTrials.gov

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Healthy
Interventions
DRUG

PF-03526299

dry powder for inhalation, 1.396 mg, BID for 14 days

DRUG

PF-03526299

dry powder for inhalation, 4 mg, BID for 14 days

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY